1. Insmed (INSM)

Insmed’s pipeline in rare diseases and respiratory treatments has shown steady progress. Also, recent trial updates have boosted confidence in long‑term revenue potential. BRINSUPRI (brensocatib), an oral DPP-1 inhibitor, has achieved robust commercial growth following its FDA approval for non-cystic fibrosis bronchiectasis. Insmed anticipates the drug will generate over $1 billion in 2026 sales and continues to seek regulatory approvals in Japan and the U.K.

Last month, Mizuho analyst Graig Suvannavejh cut Insmed’s target to $192 but kept a Buy rating, saying the stock’s pullback makes it look like a buying chance.

Turning to Wall Street, Insmed stock has a Strong Buy consensus rating based on 19 Buys assigned in the last three months. The average INSM stock price target of $199.89 implies a 79.11% upside potential.

2. Boston Scientific (BSX)